AstraZeneca's Drug Will Become the New Clinical Gold Standard by 2012 for the Treatment of Metastatic Hormone-Refractory Prost...( Differences in Prescribing Patterns W...),Health
Differences in Prescribing Patterns Were Observed Between U.S. and European Oncologists, According to a New Report from Decision Resources
WALTHAM, Mass., Jan. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that AstraZeneca's zibotentan will become Decision Resources' proprietary clinical gold standard by 2012 and through 2017 for the treatment of metastatic hormone-refractory prostrate cancer due to its competitive advantages in overall efficacy, safety and tolerability and delivery measures over the current gold standard, Sanofi-Aventis' Taxotere. Zibotentan also has a significant advantage in terms of delivery over all current and emerging therapies because it is likely to be used as an oral monotherapy.
"Interviewed key opinion leaders' optimism for zibotentan's Phase II survival data combined with our survey results make zibotentan the most likely agent to supplant Sanofi-Aventis' Taxotere as our gold standard treatment for metastatic hormone-refractory prostate cancer patients," stated Natalia Reoutova, M.Sc., analyst at Decision Resources.
The new report entitled Metastatic Hormone-Refractory Prostate Cancer: Physicians Optimistic About Targeted Therapies also finds that significant differences were observed between U.S. and European oncologists' prescribing patterns, which highlight European oncologists' greater price sensitivity compared to their U.S. counterparts.
About the Report
Metastatic Hormone-Refractory Prostate Cancer: Physicians Optimistic About Targeted Therapies is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
<
'/>"/>
| SOURCE Decision Resources Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Lost Your Job in Retail? Why Not Operate Your Own Business in 2009! Invest in You. Become an Entrepreneur!
2. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
3. Micro-Preemie Survives to Become March of Dimes 2009 National Ambassador
4. Zumas Rescue Ranch becomes a Federal 501C3
5. MinuteClinic Becomes Participating Provider With Blue Cross and Blue Shield of Florida
6. Medscape Physician Connect Becomes Largest Online Physician Social Network with More than 100,000 Physicians
7. Dental Network of America Becomes Largest National Dental Network in the U.S.
8. Mega Pediatric Group Allows Doctors to Focus on Patient Care as the Business Side of Private Practice Becomes More Difficult to Sustain
9. When the Caregiver Becomes the Patient
10. K-State helps nursing home staff become comfortable with residents sexual expression
11. 26 percent of sleepless children become overweight
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |